Description: PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer's; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer's disease, multiple sclerosis, and Parkinson's disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company's medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Home Page: www.puretechhealth.com
6 Tide Street
Boston,
MA
02210
United States
Phone:
617 482 2333
Officers
| Name | Title |
|---|---|
| Ms. Daphne Zohar | Founder, CEO & Exec. Director |
| Dr. Bharatt M. Chowrira J.D., Ph.D. | Pres, Sec., Chief Bus. Fin. & Operating Officer and Exec. Director |
| Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD | Co-Founder & Non-Exec. Director |
| Dr. Bennett M. Shapiro M.D. | Co-Founder & Board Advisor |
| Dr. David R. Elmaleh Ph.D. | Co-Founder & Sr. Advisor |
| Dr. Joseph B. Bolen | Chief Scientific Officer |
| Ms. Allison Mead Talbot | Head of Communications & Investor Relations |
| Mr. Spencer Ball | Sr. VP of HR |
| Dr. Eric Elenko Ph.D. | Chief Innovation & Strategy Officer |
| Ms. Aleksandra Filipovic M.D., Ph.D. | Head of Oncology |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6089 |
| Price-to-Sales TTM: | 51.2299 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 95 |